Acrivon Therapeutics (ACRV) Other Operating Expenses (2021 - 2022)
Acrivon Therapeutics (ACRV) posted quarterly Other Operating Expenses of -$8.5 million for Q4 2022, down 299.16% year-over-year from $4.3 million in Q4 2021, and down 188.81% quarter-over-quarter from $9.6 million in Q3 2022.
Acrivon Therapeutics (ACRV) Other Operating Expenses (2021 - 2022) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Other Operating Expenses for 2 consecutive years, with -$8.5 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Other Operating Expenses fell 299.16% year-over-year to -$8.5 million; the TTM figure through Sep 2023 stood at -$8.5 million (down 131.52% YoY), while the FY2021 annual figure was $10.7 million, changed N/A from the prior year.
- Other Operating Expenses slipped to -$8.5 million in Q4 2022 per ACRV's latest filing, from $9.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $9.6 million in Q3 2022 and bottomed at -$8.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -8.50 Mn |
| Sep 30, 2022 | 9.58 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 7.21 Mn |
| Dec 31, 2021 | 4.27 Mn |
| Sep 30, 2021 | 2.67 Mn |